Anyone who has spent significant time in biotech understands that periods of abundant capital are never permanent. The industry moves through cycles of enthusiasm and retrenchment, but the current environment signals a meaningful rebound in investor appetite. After the funding constraints of 2022 to 2024, biotech venture investment rebounded strongly in late 2025, supported by renewed M&A activity, improving public markets, and sustained demand for innovative therapeutic assets, and 2026 is looking like a banner year. READ MORE
Street Address
City, State, Zip
770-315-6331
executive compensation - venture capital - news
Your Custom Text Here
Summary Block
